UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Editorial: Precision medicine for acute myeloid leukemia

Frontiers in oncology, 2023-07, Vol.13, p.1233757-1233757

2023

Volltextzugriff (PDF)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Frontiers in oncology, 2022-09, Vol.12, p.1020185-1020185

2022

Volltextzugriff (PDF)

Harnessing NK Cells for Cancer Treatment

Frontiers in immunology, 2019-12, Vol.10, p.2836-2836

2019

Volltextzugriff (PDF)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e0109137

2023

Volltextzugriff (PDF)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes

Cancers, 2020-11, Vol.12 (12), p.3504

2020

Volltextzugriff (PDF)

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents

Haematologica (Roma), 2018-01, Vol.103 (1), p.80

2018

Volltextzugriff (PDF)

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment

Haematologica (Roma), 2022-06, Vol.107 (6), p.1410

2022

Volltextzugriff (PDF)

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia

Haematologica (Roma), 2017-09, Vol.102 (9), p.e348

2017

Volltextzugriff (PDF)

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire

Frontiers in immunology, 2023-02, Vol.14, p.1111419-1111419

2023

Volltextzugriff (PDF)

Harnessing Immune Response in Acute Myeloid Leukemia

Journal of clinical medicine, 2023-09, Vol.12 (18), p.5824

2023

Volltextzugriff (PDF)

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience

Cancers, 2023-07, Vol.15 (13), p.3457

2023

Volltextzugriff (PDF)

Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia

Leukemia research, 2016-04, Vol.43, p.49-50

2016

Volltextzugriff (PDF)

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients

American journal of hematology, 2016-08, Vol.91 (8), p.755-762

2016

Volltextzugriff (PDF)

Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives

BioScience Trends, 2017/02/28, Vol.11(1), pp.110-114

2017

Volltextzugriff (PDF)

P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE

HemaSphere, 2023-08, Vol.7 (S3), p.e7714084-n/a

2023

Volltextzugriff (PDF)

S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

HemaSphere, 2023-08, Vol.7 (S3), p.e4683875-n/a

2023

Volltextzugriff (PDF)

P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

HemaSphere, 2023-08, Vol.7 (S3), p.e89713c5-n/a

2023

Volltextzugriff (PDF)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

HemaSphere, 2023-08, Vol.7 (S3), p.e997112b-n/a

2023

Volltextzugriff (PDF)

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD + -Lowering Agents

Antioxidants, 2023-02, Vol.12 (2), p.494

2023

Volltextzugriff (PDF)

Safety and efficacy of 90Yttrium‐Ibritumomab‐Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study

British journal of haematology, 2014-03, Vol.164 (5), p.710-716

2014

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(106)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Humans
(33)
Hematology
(30)
Oncology
(19)
Male
(16)
Middle Aged
(15)
Female
(14)
Adult
(13)
Aged
(13)
Acute Myeloid Leukemia
(11)
Treatment Outcome
(9)
Hematopoietic Stem Cell Transplantation
(8)
Leukemia
(8)
Leukemia, Myeloid, Acute - Genetics
(8)
Young Adult
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Leukemia, Myeloid, Acute - Therapy
(7)
Prognosis
(7)
Retrospective Studies
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Editorial: Precision medicine for acute myeloid leukemia

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Harnessing NK Cells for Cancer Treatment

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire

Harnessing Immune Response in Acute Myeloid Leukemia

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3 -ITD in NPM1 Mutated AML, Irrespectively of FLT3 -ITD Allelic Burden

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience

Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients

Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives

P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW‐RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD

S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD + -Lowering Agents

Safety and efficacy of 90Yttrium‐Ibritumomab‐Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study

Suchergebnisse filtern